U.S. Construction Stock News

PTC Therapeutics, Inc. recently reported second-quarter 2026 results showing revenue of US$360.52 million and net income of US$83.5 million, while also raising its full-year 2026 total revenue outlook to US$1.18 billion–US$1.28 billion and appointing long-time executive Hege Sollie-Zetlmayer to its board of directors. The combination of a profitable quarter, higher revenue guidance, and added board experience from a former Chief Human Resources Officer may influence how investors assess PTC...

PNC Financial Services Group (PNC) is back in focus after PNC Bank opened its 50th new branch under a multi year, $2b expansion plan and hired industry veteran Arne Jahn to lead its metals and mining sector coverage. See our latest analysis for PNC Financial Services Group. Against this backdrop, PNC Financial Services Group’s recent business moves sit alongside a 90 day share price return of 21.14% and a 1 year total shareholder return of 37.32%. The 3 year total shareholder return of...

Ciena (CIEN) is back in focus after two recent networking announcements, as investors weigh what new DWDM deployments in the UAE and a quantum safe encryption trial in the US might mean for the stock. See our latest analysis for Ciena. Those two networking wins arrive after a sharp pullback in Ciena’s share price. It is down 32.94% over 90 days and 15.89% over 30 days, even though the year-to-date share price return is 57.49% and the 1-year total shareholder return is very large. This...

Hamilton Lane stock has fallen 32.6% over the past year, yet the current valuation checks now suggest the shares no longer look obviously expensive or obviously cheap. After this reset, investors are weighing a recent bounce against what the broader valuation picture implies for the next phase. Over the last 12 months the share price declined 32.6%, which puts recent gains into the context of a stock still well below where it traded a year ago. Hamilton Lane’s recent move to acquire a US$270...

The market just rewrote the Alamar Biosciences story in one session. The stock surged 30.7% to US$36.57 after its first post‑IPO quarter as a listed company, even though the business is still running losses. That kind of jump puts expectations on a different level. The headline from these earnings is simple. Revenue reached US$29.4m in Q2 and gross margin hit 60%, an all time high for the company, while Alamar reported a net loss of US$13.2m. For a high growth proteomics platform, this...

Becton, Dickinson and Company reported its third-quarter fiscal 2026 results, with sales rising to US$4,983 million while quarterly and year-to-date net income fell compared with the prior year, and it updated full-year 2026 guidance to expect low single-digit plus GAAP revenue growth. This was the first full quarter after spinning off its biosciences and diagnostics business, highlighting a more focused medical technology portfolio and new drug-delivery collaborations such as the...

HCA Healthcare stock has produced a 75.1% return over the past five years, yet current valuation checks suggest the shares may still trade at a discount to an estimate of intrinsic value based on a Discounted Cash Flow (DCF) approach and earnings multiples. At the same time, recent headlines around worker pay, staffing, leadership changes and new urgent care acquisitions give investors more to weigh as they think about what that valuation gap really reflects. A 75.1% return over five years...

In the second quarter of 2026, Turning Point Brands reported higher sales of US$142.96 million but lower net income of US$3.6 million, while also completing its February 2020 share repurchase program with 2,471,405 shares bought back for US$83.01 million. Despite the earnings pressure, the company raised its full-year 2026 Modern Oral guidance, lifting projected gross sales to US$330 million–US$350 million and net sales to US$260 million–US$270 million, underscoring the growing importance of...

Legend Biotech entered this earnings release as a pressured growth story, with the stock down sharply over the past three months. Today the mood shifted. Shares rose about 6% after the market absorbed a straightforward set of results. Q2 moved from a loss in Q1 to positive basic earnings per share and reported quarterly revenue of US$387.5m. For a biotech widely viewed as long on promise and short on profits, that move into positive earnings on a quarterly basis is the key detail. The rest of...

In the second quarter of 2026, Glaukos Corporation reported sales of US$185.61 million versus US$124.12 million a year earlier, with its basic loss per share from continuing operations narrowing to US$0.31 from US$0.34. Alongside this performance, Glaukos raised its 2026 net sales guidance to a range of US$680 million to US$700 million, signaling management’s increased confidence in the company’s revenue outlook despite ongoing losses. We’ll now explore how Glaukos’ raised full-year sales...

Berkshire Hathaway reported past second-quarter 2026 results showing revenue of US$101.81 billion and net income of US$25.67 billion, with earnings from continuing operations per share rising sharply from the prior year. Under new CEO Greg Abel, Berkshire shifted from hoarding cash to actively deploying capital through its largest share repurchases in nearly two years, renewed net stock buying, and sizable commitments such as a US$10 billion investment in Alphabet and the Taylor Morrison...

In August 2026, Schrödinger, Inc. reported that second-quarter 2026 revenue rose to US$58.89 million and swung from a prior-year loss to net income of US$5.98 million, while also filing a US$46.95 million shelf registration for 3,000,000 common shares related to its employee stock ownership plan. On the same day, Bristol Myers Squibb announced it would deploy Schrödinger’s agentic AI co-scientist Bunsen across its research organization, expanding a long-running collaboration and spotlighting...

Why FuelCell Energy Stock Is Back in Focus FuelCell Energy (FCEL) is drawing renewed attention after its carbon capture platform was highlighted for reducing emissions while producing extra electricity, without requiring full power plant replacements. See our latest analysis for FuelCell Energy. FuelCell Energy’s carbon capture update comes after a volatile run, with the share price down 14.67% over the past week and 8.70% over the past month, yet still up 135.01% year to date. The 1 year...

Plug Power jumped about 5% to US$2.22 into the close, which indicates traders responded positively to the headline. The story behind that move is a sharp reset in sentiment around margins and cash burn. Q2 revenue landed at US$178.3m with gross margin roughly at breakeven instead of the deep losses investors had grown used to. Net cash usage fell to about US$61m in the quarter. The question now is whether this early margin repair and slower cash burn justify the renewed optimism in a stock...

GoodRx Holdings (NasdaqGS:GDRX) appointed Justin Fengler as Chief Financial Officer and Treasurer, succeeding Christopher McGinnis. Fengler will hold the CFO and Treasurer roles alongside his existing position as Chief Strategy & Operations Officer. The leadership change centralizes financial, strategy, and operations responsibilities under a single executive. This kind of leadership reshuffle is one piece of a broader story about how companies think about capital allocation and income...

Chicago Atlantic Real Estate Finance shares barely moved after earnings, slipping only 0.05% to about US$10.23. For a stock tied to high yield cannabis credit, that calm response sits at odds with what really jumped off the page. The headline is not revenue or basic earnings per share. It is the squeeze between very high dividends and the cash needed to support them. Distributable earnings per share came in at US$0.44 while the declared dividend was US$0.47. That gap, alongside already...

Why Alkami Technology Stock Is Back in Focus Alkami Technology (ALKT) is drawing fresh attention after reporting second quarter results, issuing new revenue guidance, and announcing data focused partnerships with Arkatechture and Plaid that expand its digital banking offering. See our latest analysis for Alkami Technology. Alkami Technology's recent earnings, guidance and new data partnerships have coincided with building momentum in the share price, with a 30 day share price return of 14.29%...

HighPeak Energy shares have quietly climbed, up about 4% today and more than 20% over the past month, as investors reassess a stock that has been priced for trouble. The tension is simple: the market still sees a highly discounted, volatile small cap, while the latest quarter shows an oil producer that just reported solid profits and cash generation. The headline is the earnings swing. HighPeak Energy moved from a loss in recent quarters to Q2 basic earnings per share of about US$0.60 on...

In the second quarter of 2026, Appian Corporation reported revenue of US$203.26 million, up from US$170.64 million a year earlier, while net loss widened to US$11.82 million and basic loss per share from continuing operations was US$0.16. At the same time, Appian raised its 2026 revenue outlook and highlighted strengthening demand for its AI-powered automation platform, and also partnered with Synechron to launch an Open Underwriting Stack aimed at speeding insurers’ underwriting...

Hancock Whitney stock has delivered a 107.3% return over the past three years. The current Excess Returns intrinsic value estimate now points to the shares trading at a 43.7% discount, while traditional earnings-based multiples look roughly in line with the market. That mix leaves Hancock Whitney looking neither like a straightforward bargain nor clearly expensive on a headline basis. Over the past three years Hancock Whitney has returned 107.3%, which puts recent gains front and center when...

NetApp (NTAP) is back in focus after its recent acquisition of JetStream Software and ahead of its upcoming fiscal Q1 2027 earnings release, which is scheduled for after the market close on September 2, 2026. See our latest analysis for NetApp. NetApp’s recent acquisition of JetStream Software and the approaching Q1 2027 earnings update come on the back of strong momentum, with a 30 day share price return of 17.53% and a 1 year total shareholder return of 87.37%. This suggests investors have...

PPL (PPL) has moved into focus after its recent Q2 2026 earnings report and reaffirmed full year guidance. The company is tying current performance to long term data center driven power demand. See our latest analysis for PPL. At a share price of US$35.28, PPL has seen modest short term moves around its Q2 2026 earnings and guidance reaffirmation, while the 3 year total shareholder return of 53.16% contrasts with a slightly negative 1 year total shareholder return. If data center driven power...

With the Fed’s tone turning tougher and Beth Hammack openly backing further rate hikes, interest rates sit at the heart of the stock market story again. Higher borrowing costs can squeeze some companies while opening the door for others that earn more from lending and underwriting. This article walks through three US financial stocks from a focused screener, showing how each could be positioned as policy tightens. The three stocks covered below are only a starting sample from this theme, and...

Why SELLAS Life Sciences Group Stock Is Back On Investors’ Radars SELLAS Life Sciences Group (SLS) has drawn fresh attention after reporting second quarter 2026 results that showed a net loss of US$9.61 million and updated loss per share figures from continuing operations. See our latest analysis for SELLAS Life Sciences Group. Alongside the latest quarterly loss, investors have been watching SELLAS Life Sciences Group’s share price closely. The stock has pulled back over the past week and...